Premium
Ultra–low‐dose radiotherapy for definitive management of ocular adnexal B‐cell lymphoma
Author(s) -
Pinnix Chelsea C.,
Dabaja Bouthaina S.,
Milgrom Sarah A.,
Smith Grace L.,
Abou Zeinab,
Nastoupil Loretta,
Romaguera Jorge,
Turturro Francesco,
Fowler Nathan,
Fayad Luis,
Westin Jason,
Neelapu Sattva,
Fanale Michelle A.,
Rodriguez Maria A.,
Hagemeister Frederick,
Ju Lee Hun,
Oki Yasuhiro,
Wang Michael,
Samaniego Felipe,
Chi Linda,
Esmaeli Bita
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25149
Subject(s) - medicine , radiation therapy , head and neck , nuclear medicine , complete response , lymphoma , mantle cell lymphoma , stage (stratigraphy) , radiology , surgery , chemotherapy , paleontology , biology
Background. The purpose of this study was to report the response to and toxicity of ultra–low-dose radiotherapy (RT) for B-cell ocular adnexal lymphoma (OAL). Methods. We conducted a retrospective review of patients with indolent B-cell and mantle cell OAL treated with 4 Gy to the orbit(s) in two 2-Gy fractions. Disease response was assessed clinically and/or radiographically at 2 to 4-month intervals after RT. Data collected included rates of overall response, complete response (CR), partial response (PR), and treatment-related toxic effects. Results. Twenty-two patients (median age, 65 years) had the following histologic subtypes: mucosa-associated lymphoid tissue (MALT; 14 patients; 64%); follicular lymphoma (5 patients; 23%); mantle cell lymphoma (MCL; 2 patients; 9%); and unclassifiable (1 patient, 4%). The overall response rate was 100%; 19 patients (86%) had a CR and 3 patients (14%) had a PR. The only acute toxic effect was grade 1 dry eye syndrome in 1 patient. Conclusion. Ultra–low-dose RT in patients with OAL is associated with high response rates and minimal toxic effects, and is much shorter in duration and cost. VC 2017 Wiley Periodicals, Inc. Head Neck 39: 1095– 1100, 2017